KRAS, BRAF and SACT prior to HIPEC; HIPEC chemotherapy type (oxaliplatin or mitomycin); poor and/or mucinous tumour differentiation; and the presence of signet cells in tumour did not significantly predict OS (p > 0.05). Here, KRAS is linked to neoplasm.